Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Policy Changes Could Enhance Affordability of Esketamine for Treatment-Resistant Depression

2w ago August 29, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

A research team from HKUMed and collaborating institutions has identified policy changes that could make esketamine nasal spray more affordable for treatment-resistant depression in Hong Kong. This development highlights the potential for improved mental health treatment accessibility, which could have implications for similar healthcare policies in Iran. The affordability of mental health treatments is crucial for addressing the growing mental health crisis in Iran.

🔍 Quick Context Guide
💡 Bottom Line: Policy changes identified in Hong Kong could enhance the affordability of innovative mental health treatments, with potential implications for similar efforts in Iran.

👥 Key Players

LKS Faculty of Medicine, University of Hong Kong MENTIONED
Research institution leading the study
"Their research could influence mental health policy and treatment accessibility in various regions, including Iran."
The Chinese University of Hong Kong MENTIONED
Collaborating research institution
"Contributes to the academic credibility and depth of the research findings."
New York University MENTIONED
Collaborating research institution
"Brings international expertise and perspective on mental health treatments."
Newcastle University MENTIONED
Collaborating research institution
"Adds to the global research network focused on innovative mental health solutions."

📰 What Happened

A research team has identified policy changes that could make esketamine nasal spray more affordable for adults with treatment-resistant depression in Hong Kong. This finding suggests a pathway to improve mental health treatment accessibility.

  • Esketamine is a novel rapid-acting treatment for treatment-resistant depression.
  • The study involved collaboration among multiple prestigious universities.

💡 Why It Matters

🇮🇷 For Iran: This research could inspire Iranian policymakers to consider similar approaches to enhance mental health treatment affordability amidst a growing mental health crisis.
🌍 Regional: Improved mental health policies in Hong Kong may set a precedent for other countries in the region facing similar challenges.
🌐 International: The findings could influence global mental health treatment strategies and policies, particularly in how new treatments are made accessible.

📚 Background

Treatment-resistant depression is a significant mental health issue that affects many individuals, and innovative treatments like esketamine are emerging as potential solutions. Accessibility and affordability remain critical challenges in mental health care worldwide.

Mental health policy Treatment-resistant depression
📡 Source: NEUTRAL
📊 Confidence: 70%
The article presents research findings from reputable institutions, suggesting a balanced perspective on the implications of the study.

A joint research team led by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with The Chinese University of Hong Kong, New York University and Newcastle University, has found that a combination of policies and service measures could enhance the value and affordability of esketamine nasal spray, a novel rapid-acting treatment for adults with treatment-resistant depression (TRD) in Hong Kong.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →